Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bimatoprost 0.03% sterile solution
Bimatoprost 0.03% sterile · 1 trial · 1 indication
The GEA scale is an investigator-graded 4-point ordinal scale of overall eyelash prominence (1 \[minimal\], 2 \[moderate\], 3 \[marked\], 4 \[very marked\])
The GEA scale is an investigator-graded 4-point ordinal scale of overall eyelash prominence (1 \[minimal\], 2 \[moderate\], 3 \[marked\], 4 \[very marked\])
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bimatoprost 0.03% solution |
| 2 | PLACEBO_COMPARATOR | Vehicle solution |
| Name | Type | Description |
|---|---|---|
| Bimatoprost 0.03% sterile solution | DRUG | Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily. |
| vehicle sterile solution | DRUG | Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily |
Inclusion Criteria: * Dissatisfaction with eyelash prominence, * Eyelash prominence assessment of minimal or moderate, * Ability to provide written informed consent Exclusion Criteria: * Subjects without visible lashes, * Asymmetrical (uneven lashes or longer on one side than the other) eyelashes...
Bimatoprost 0.03% sterile is used to increase overall eyelash prominence. It is a small molecule developed by AbbVie Inc. (ticker ABBV) and studied in adults aged 18 years and older. The Phase 3 program enrolled 278 participants in the United States and Canada.
Bimatoprost 0.03% sterile targets PTGFR, the prostaglandin F receptor, where it acts as an agonist. This receptor activity underlies its intended effect on eyelash prominence in the studied indication.
Bimatoprost 0.03% sterile is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the company associated with the Phase 3 development program for this eyelash indication.
Bimatoprost 0.03% sterile is in Phase 3 development. It is an investigational small molecule and is not described as approved. The Phase 3 trial has completed, and no trials are currently listed as active.
Bimatoprost 0.03% sterile was studied in the Phase 3 trial NCT00693420, titled Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence. That trial is completed, was randomized, double blind, and placebo controlled, and enrolled 278 participants across the United States and Canada.
Yes. Bimatoprost 0.03% sterile and Bimatoprost 0.03% sterile solution refer to the same product. The alternative name describes the same sterile solution formulation of bimatoprost at 0.03% strength.